Skip to main content

Homatropine ophthalmic Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 24, 2023.

Applies to homatropine ophthalmic: ophthalmic solution.

Side effects include:

Elevated IOP, transient stinging, burning. With prolonged administration, local irritation (characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and eczematoid dermatitis ), thirst, dry mouth, increased light sensitivity of eyes.

For Healthcare Professionals

Applies to homatropine ophthalmic: compounding powder, ophthalmic solution.

General

The most frequently reported side effects were transient stinging/burning upon instillation and increased sensitivity to light.[Ref]

Ocular

Common (1% to 10%): Transient burning, transient stinging, increased sensitivity to light

Uncommon (0.1% to 1%): Eye irritation

Rare (0.01% to 0.1%): Local irritation, vascular congestion, edema, exudates, eczematoid dermatitis, follicular conjunctivitis

Postmarketing reports: Conjunctivitis, photophobia, mydriasis prolonged, eye pain, eye edema, eye discharge, eye irritation, ocular hyperemia[Ref]

Gastrointestinal

Rare (0.01% to 0.1%): Thirst, dryness of mouth

Frequency not reported: Abdominal distention infants, gastrointestinal motility diminished, salivary secretion decreased, sweat gland secretion decreased[Ref]

Nervous system

Frequency not reported: Ataxia, incoherent speech, hyperactivity, seizure, unusual drowsiness

Postmarketing reports: Somnolence[Ref]

Psychiatric

Frequency not reported: Restlessness, hallucination, disorientation, failure to recognize people

Postmarketing reports: Confusion[Ref]

Genitourinary

Frequency not reported: Urinary retention[Ref]

Respiratory

Frequency not reported: Secretion decreased in pharynx/bronchi/nasal passages, rapidly progressive respiratory depression[Ref]

Other

Frequency not reported: Hyperpyrexia[Ref]

Cardiovascular

Frequency not reported: Tachycardia, vasodilation, hypotension

Postmarketing reports: Heart rate increased[Ref]

Dermatologic

Frequency not reported: Skin rash[Ref]

References

1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Homatropine Hydrobromide (homatropine ophthalmic). OCuSOFT. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer